•Dual GIP-GLP-1 RA shows superior efficacy in lowering POAG, OHT risk•Samsung Biopeis and Regeneron settle EYLEA biosimilar US patent dispute•Pandorum Tech raises $18M to expand operations for bioengineered cornea•Arctic Vision acquires MDCO Technology's ophthalmic device business•Iron overload may increase glaucoma risk•Dual GIP-GLP-1 RA shows superior efficacy in lowering POAG, OHT risk•Samsung Biopeis and Regeneron settle EYLEA biosimilar US patent dispute•Pandorum Tech raises $18M to expand operations for bioengineered cornea•Arctic Vision acquires MDCO Technology's ophthalmic device business•Iron overload may increase glaucoma risk
HEADLINES
FEATURED
NO-donating bimatoprost formulation remains on track for a summer 2026 new drug application submission.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
